Minesh Kothari, Author at Orphalan SA
WEBHit enter to search or ESC to close. Close Search. search
Cookie Policy - Orphalan SA
WEBAt Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases
WEBOrphalan do not operate company cars but instead offers a car allowance. We are investigating how we can encourage employees to adopt GHG free cars at the earliest
Our Presence - Orphalan SA
WEBHit enter to search or ESC to close. Close Search. search
WEBOrphalan UK Ltd. has taken steps to understand all potential modern slavery risks related to its business, in accordance with Section 54 of the UK Modern Slavery Act 2015. We are committed to preventing slavery and human trafficking, both in our own corporate activities and our supply chain. We take measures to ensure
This morning, Dr Weiss presented our Phase 3 data at @EASL
WEBFriday 25 June Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine. This is the first trial of its...
WEBOrphalan 226 Boulevard Voltaire 75011 Paris Francia Responsable de la fabricación Delpharm Evreux 5 rue du Guesclin 27000 Evreux, Francia Fecha de la última revisión de este prospecto 07/2021. Title: FG0051687-012-01.indd Author: pidcmg Created Date:
Study Archives - Orphalan SA
WEBHit enter to search or ESC to close. Close Search. search
Orphalan SA
WEBOrphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 May 2022 – Orphalan...
admin, Author at Orphalan SA
WEBOrphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3...